BioCryst Pharmaceuticals, Inc. (BMV:BCRX)

Mexico flag Mexico · Delayed Price · Currency is MXN
197.50
0.00 (0.00%)
At close: May 23, 2025
99.78%
Market Cap 45.11B
Revenue (ttm) 10.29B
Net Income (ttm) -1.09B
Shares Out n/a
EPS (ttm) -5.30
PE Ratio n/a
Forward PE 36.09
Dividend n/a
Ex-Dividend Date n/a
Volume 1,900
Average Volume 555
Open 197.00
Previous Close n/a
Day's Range 197.00 - 197.50
52-Week Range 138.00 - 215.00
Beta n/a
RSI 49.91
Earnings Date Aug 4, 2025

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1986
Employees 580
Stock Exchange Mexican Stock Exchange
Ticker Symbol BCRX
Full Company Profile

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.